Alam Manzar, Hasan Gulam Mustafa, Eldin Sayed M, Adnan Mohd, Riaz Muhammad Bilal, Islam Asimul, Khan Ilyas, Hassan Md Imtaiyaz
Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi 110025, India.
Department of Biochemistry, College of Medicine, Prince Sattam Bin Abdulaziz University, P.O. Box 173, Al-Kharj 11942, Saudi Arabia.
Biomed Pharmacother. 2023 May;161:114452. doi: 10.1016/j.biopha.2023.114452. Epub 2023 Mar 4.
Non-small cell lung carcinoma (NSCLC) is the most common malignancy worldwide. The signaling cascades are stimulated via genetic modifications in upstream signaling molecules, which affect apoptotic, proliferative, and differentiation pathways. Dysregulation of these signaling cascades causes cancer-initiating cell proliferation, cancer development, and drug resistance. Numerous efforts in the treatment of NSCLC have been undertaken in the past few decades, enhancing our understanding of the mechanisms of cancer development and moving forward to develop effective therapeutic approaches. Modifications of transcription factors and connected pathways are utilized to develop new treatment options for NSCLC. Developing designed inhibitors targeting specific cellular signaling pathways in tumor progression has been recommended for the therapeutic management of NSCLC. This comprehensive review provided deeper mechanistic insights into the molecular mechanism of action of various signaling molecules and their targeting in the clinical management of NSCLC.
非小细胞肺癌（NSCLC）是全球最常见的恶性肿瘤。信号级联通过上游信号分子的基因修饰被激活，这会影响细胞凋亡、增殖和分化途径。这些信号级联的失调会导致癌症起始细胞增殖、癌症发展和耐药性。在过去几十年中，人们在NSCLC治疗方面付出了诸多努力，增进了我们对癌症发展机制的理解，并朝着开发有效治疗方法迈进。转录因子和相关途径的修饰被用于开发NSCLC的新治疗方案。推荐开发针对肿瘤进展中特定细胞信号通路的设计抑制剂用于NSCLC的治疗管理。这篇综述对各种信号分子的作用分子机制及其在NSCLC临床管理中的靶向作用提供了更深入的见解。
